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Trefoil Factor 1 (TFF1) is a small secreted protein, belonging to the 
trefoil factor family, characterized by a conserved ―trefoil domain‖ containing 
six cysteine residues that form a three loop disulfide structure. It is expressed 
in the gastrointestinal tract, where plays an essential role in mucosal 
protection through mucous-barrier formation, and also in mucosal repair 
through promotion of restitution after injury. In recent years clinical and 
experimental studies have shown an active function of the trefoil peptides in 
the genesis of neoplastic processes. TFF1 is mainly associated with breast 
cancer and gastric cancer (GC), but have been described changes in its 
expression levels also in pancreatic, lung, prostate and colorectal cancer. 
TFF1 had been described as a tumour suppressor gene in gastric cancer, but 
it is markedly elevated in gastric mucosa with atypical hyperplasia, diffuse-tye 
gastric cancer and with lymph node metastasis. However, the distinct 
signaling pathways have not been fully elucidated, nor have definitive 
functional receptors for trefoil proteins been identified. 
In this PhD project, experiments were performed to understand the 
role of TFF1 in human GC development with particular attention to invasion 
and epithelial-mesenchimal transition (EMT) processes. Previously it has 
been demonstrated that TFF1 selectively  binds copper ions, which influence 
homodimer formation and its biological activity. Here, by using TFF1 
recombinant protein on AGS cell line and a TFF1 over-expressing clone 
(AGS-AC1), we demonstrated that TFF1 stimulated invasion of GC cell lines. 
The pro-invasive activity of TFF1 was strictly regulated by copper and was 
associated with a greater MMP-2 activity. We also reported that TFF1 was 
implicated in the occurrence of EMT, not only in the GC models but also in a 
prostate cancer cell line, in a same manner with a reduction of epithelial 
markers such as E-cadherin and cytokeratins 8 and 18 and an increase of  
mesenchymal ones such as vimentin. Additionally, in hypoxic condition, a 
significant increase of TFF1 expression was associated with hypoxia-related 
mesenchymal/metastatic process.  
Furthermore, TFF1 regulated its own expression, in normoxic as 
hypoxic condition, with an autoinduction mechanism and promoting DNA 
demethylation.  
Finally, we investigated the relationship between TFF1 and the N-
formyl peptide receptors (FPR1, FPR2 and FPR3), involved in innate 
immunity, inflammation and cancer, including GC. We found that recombinant 
TFF1 protein in AGS cells induced FPR expression and FPRs influenced pro-
invasive activity of TFF1. 
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BCS: Bathocuproine sulfate 
Boc: t-Boc-Met-Leu-Phe 
bp: base pair 
CCO: cytochrome c oxidase  
CCS: copper chaperones  
CK: cytokeratin 
CoCl2: cobalt chloride 
COX-2: Cyclooxygenase-2 
Ctr1: copper transporter 1 
Cu: copper 
CuCl2: copper(II) chloride 
Cu,Zn-SOD: Cu,Zn-superoxide dismutase  
DMT1: Divalent Metal Transporter 1  
Dox: doxycycline  
ECM: Extracellular Matrix 
EGF: Epidermal Growth Factor 
EGFR: Epidermal Growth Factor Receptor 
EMT: Epithelial to Mesenchymal Transition  
ERE. Estrogen-responsive Element  
ERK: Extracellular signal-Regulated Protein 
FALS: familial amyotropic lateral sclerosis  
FAK: Focal Adhesion Kinase 
FBS: Fetal Bovine Serum 
FGF: Fibroblast Growth Factor 
fMLP: formylMethionilLeucilPhenylalanine 
FPR: Formyl Peptide Receptor 
GC: gastric cancer 
GI: gastrointestinal  
GKN2: Gastrokine 2  
HIF1α: Hypoxia Induced Factor 1 α 
HSP70: Heat-Shock Protein 70  
HRM: High Resolution Melting  
LOH: loss of heterozygosity  
LOX: Lysyl Oxidase 
MEMO: mediator of ErbB2-driven cell motility 
MMP: Membrane Metallo-Proteases 
NF-kB: Nuclear Factor kappa-light-chain-enhancer of activated B cells 
PBS: Phosphate Buffer Saline 
PC: Prostate cancer  
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PI3K: Phosphoinositide 3-kinase  
Rho: Ras homologue 
ROS: reactive oxygen species  
SD: standard deviation 
SPARC: secreted protein acidic and rich in cysteine  
TGFβ: Trasforming Growth Factor β 
TPA: 12-O-tetradecanoylphorbol 13-acetate  
TRE TPA-response element  
VEFG: Vascular Endothelial Growth Factor 
WT: Wild Type  
ZEB: Zinc finger E-box binding homeobox      
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CHAPTER 1 
 
TREFOIL FACTORS FAMILY 
 
1.1  Introduction 
The Trefoil Factors Family (TFF) is a group of three small human 
proteins: gastric peptide TFF1 (pS2), spasmolytic peptide TFF2 (SP) and 
intestinal trefoil factor TFF3 (ITF). The TFF factors are resistant to the 
proteases abundantly secreted in the gastrointestinal tract and are involved in 
the protection and repair processes of the mucous membranes. They share a 
structural motif, the ―trefoil domain" or P-domain, characterized by a specific 
pattern of disulphide bonds that create the characteristic three-leaved shape, 
giving the name to the group [1]. The standardized nomenclature TFF1-3 was 
introduced at a Conférence Philippe Laudat in 1996 and has replaced their 
former, often functionally misleading names, which referred to the setting 
where they were originally discovered [2]. 
TFF2, formerly known as spasmolytic polypeptide, was the first TFF to 
be isolated in the early 1980s in the porcine pancreas during the purification 
of insulin [3]. Human TFF2 was characterized later [4, 5]. 
In the same years the cloning of an estrogen-regulated gene from the 
MCF-7 human breast cancer cell line brought to the identification of pS2, now 
known as TFF1 [6]. 
TFF3, previously named Iintestinal trefoil factor/ITF, was cloned from 
rat intestinal epithelial cells in 1991 [7] and in 1993 was reported the human 
cDNA sequence [8, 9]. 
The TFFs are evolutionarily highly conserved proteins, showing more 
than 70% amino acid identity among the rodent and human TFFs (fig. 1.1) 
[10, 11]. The sequence identity and the peculiar conserved structure have 
corroborated the hypothesis of a common ancestor gene [9, 10, 12]. 
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Figure 1.1: Sequence alignment of mammalian trefoil factors. Residues completely 
conserved between the orthologues are shown in green and those with substitutions 
are shown in purple. (From Thim L. and May F. E. B., 2005.) 
 
 
1.2 Structural properties: the trefoil domain 
Trefoil peptides share common structural features. They are 
synthesised with a signal secretion sequence of 21-27 amino acid residues 
that is removed by proteolysis during passage through the endoplasmic 
reticulum. 
The characteristic three-leaved structure of the TFF domain was first 
detected by Thim [1] and it consists of a sequence of about 40 amino acids   
within which 6 conserved cysteine residues form disulphide bridges in a 1-5, 
2-4, 3-6 configuration [1, 13, 14]. TFF1 and TFF3 consist respectively of 60 
and 59 residues, and both have a single trefoil domain of 42 amino acid 
residues. Instead, TFF2 consists of 106 amino acid residues and two trefoil 
domains, respectively of 43 and 42 residues joined by a small interface 
(Figure 1.2).  
 
 
 
Figure 1.2: Sequence alignment of human trefoil factors. Residues completely 
conserved between the orthologues are shown in green and those with substitutions 
are shown in purple. (From Thim L. and May F. E. B., 2005.) 
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The secondary and tertiary structures were solved by X-ray 
crystallography and NMR studies confirming the hypothesis, previously 
postulated, of the three-loop structure (Figure 1.3) [1, 15-17].  
 
 
 
Figure 1.3: Secondary structures of human trefoil factors. Cysteine residues are 
shown in red  (From Mathelin C., Tomasetto C., Rio M. C., 2005.) 
 
 
Through these studies it was also highlighted that the domain, in 
addition to the six cysteines, has common structural elements due to the 
presence of other conserved residues: the arginine residue between the first 
two cysteines, the sequence around the second cysteine, N/DCGF/YP-V/IT/S, 
the phenylalanine after the third and fourth cysteines, and the VPWCF-P 
sequence around the sixth cysteine at the C-terminal end of the trefoil domain 
(fig. 1.2). These amino acids probably play a fundamental role in maintaining 
the geometry, the stability and functional properties of all trefoil domains. 
All the trefoil domains present a short α-helix that includes the third 
cysteine residue [16, 18, 19] and an irregular two-stranded antiparallel β-
sheet, the first strand of which is separated from the a-helix by one residue. 
The two strand comprise respectively the CCF motif and the WCF-P motif [16, 
18, 20, 21] (fig. 1.2). 
The three disulphide bonds of the trefoil domain create a stable core 
with the three loops stacked together, the third of which positioned between 
the first and second loops. In this way it forms a compact structure that gives 
to the peptides the resistance to proteases as trypsin and chymotrypsin and 
to acids and thermal degradation [3]. 
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1.3 Intra- and intermolecular bonds formation 
TFF1 and TFF3 contain also a seventh cysteine residue near the 
carboxy-terminus (Cys58 for TFF1 and Cys57 for TFF3), which confers the 
possibility to form dimers (fig. 1.4) [22-25]. TFF2, instead, has two extra-trefoil 
domain cysteine residues, Cys5 and Cys104 that form an intermolecular 
disulphide bond [1], so it is considered a natural dimer (fig. 1.4).  
 
 
Figure 1.4: Structures of human TFF1 dimer, porcine TFF2 and human TFF3 dimer. 
The structures were determined by NMR spectroscopy (TFF1 and 3) or by X-ray 
crystallography (TFF2). (From Kjellev S., 2009) 
 
 
Three different molecular forms of TFF1 were described in normal 
human gastric mucosa: TFF1 monomer (6.5 kDa), TFF1 homodimer and 
TFF1 heterodimer, a 25-kDa complex [26, 27]. The homodimer is composed 
of two monomers linked by a disulphide bond between Cys58. The two 
monomeric units in the human TFF1 dimer are not fixed, but they showed a 
mixture of different conformations [24].  
 Furthermore, in the homodimer there‘s a strongly acidic region at the 
centre of the flexible peptide linker, due to the approaching of two regions 
containing one aspartic acid and four glutamic acid residues at the carboxy-
terminal end of each monomer. It was postulated that this region of localised 
charge contributes to the constraints on the steric properties of the peptide 
near the disulphide junction [14]. Many experiments demonstrated that TFF1 
homodimer has more significant biologic activity than the monomer [26]. 
The TFF1 heterodimer is the major form present in gastric mucosa 
and the TFF1 protein partner has been identified as Gastrokine 2 (GKN2), 
also called trefoil factor interactions(z) 1 (TFIZ1), GDDR or Blottin, a secreted 
protein that contains a brichos domain and homology with pulmonary  
surfactant-associated protein C precursor [28, 29]. The TFF1 heterodimer  
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comprises one molecule each of TFF1 and GKN2, stabilised by a disulphide 
bond between the two proteins [28, 30]. TFF1 compound may have a greater 
biological activity than monomer and dimer [27]. 
Also TFF3 forms homodimers as TFF1 but, although they are very 
similar, exhibit significant differences that contribute to their biological 
activities and specificity [31]. In detail, TFF3 homodimer has a more compact 
structure than TFF1 homodimer.  
 
 
1.4 Distribution and expression of TFFs 
The main site of expression of TFFs is the gastrointestinal (GI) tract, 
where they show a cell-specific pattern of expression in distinct, often 
complementary locations. TFF1 is abundantly expressed in the stomach, in 
the superficial and foveolar epithelium [32-36]. It is also present in upper 
ducts and surface cells of Brunner‘s glands in the duodenum [37]. Generally 
the small intestine does not express TFF1, although some staining has been 
described on the tips of villi in the ileum and jejunum [38]. In the normal large 
intestine, TFF1 expression has been detected in goblet cells, near the surface 
of crypts [39] and in gall bladder has been reported some patchy epithelial 
expression [40]. Furthermore a weak TFF1 expression has been detected in 
salivary glands [33].  
Also TFF2 is mainly expressed in the stomach, in particular in mucous 
glands of body and antrum [32, 36, 41]. In duodenum, TFF2 is present in 
Brunner‘s glands acini and distal ducts [38].  
The major site of expression for TFF3 is the intestine, in particular in 
goblet cells throughout the intestine and in gland acini and distal ducts of 
Brunner‘s glands [42, 43].  
 
 
 
Figure 1.5: Table with the main sites of expression of human trefoil factors in normal 
physiological conditions. (Wong W. M., Poulsom R. and Wright N. A., 1999) 
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TFFs are essentially found in tissues containing mucus-secreting cells; 
they are co-packaged in the Golgi apparatus into mucus granules and 
secreted with mucins into the protective layer covering the mucosa, 
suggesting that their functions may be related to that of mucins. Mucins are a 
family of high molecular weight, heavily glycosylated proteins produced by 
epithelial tissues. TFFs expression is closely associated with gastrointestinal 
mucins: TFF1 is co-localised with MUC5AC, TFF2 is associated with MUC6 
and TFF3 is co-expressed with MUC2 [44]. 
Given their nature of secreted proteins, TFFs have been detected in 
several biological fluids such as gastric juice [45, 46], intestinal contents [47], 
saliva [48] and also blood and urine [49, 50]. 
Outside the GI tract, TFFs expression have been described in 
respiratory and ocular tissues [51-55], prostate [52] and female reproductive 
organs as well as in milk [52, 56, 57], lymphoid tissues [58] and brain [58, 59]. 
 
 
1.5 TFFs functions 
1.5.1 Mucosal defense 
The gastrointestinal tract is constantly threatened by potentially 
harmful agents as acid, bacteria, toxins. The gastrointestinal epithelium forms 
a physical barrier against these agents and it is essential to ensure the 
continuity of the epithelial layer. Gastric mucosal barrier is a multilayer 
system, which include a preepithelial mucus-bicarbonate barrier, an epithelial 
barrier (surface epithelial cells connected by tight junctions), and a 
subepithelial component including blood flow and nerves [60, 61]. The mucus-
bicarbonate barrier is the first line of mucosal defense, composed of mucus 
gel, bicarbonate and surfactant phospholipids [62, 63].  
The gastric mucus is a viscous gel that coats the entire gastric 
mucosa, produced by and secreted from the surface epithelial cells and 
formed by 95% water and 5% mucins. Various studies suggest that TFFs 
influence mucus gel properties. Trefoil peptides are an integral part of the 
intracellular mucus secretory vesicles; they are coexpressed and strongly 
interact with mucins, enhancing the protective properties of the mucosal 
barrier (fig. 1.6) [64, 65]. It is supposed that TFFs may cross-link with mucins 
[66]. Furthermore, they may affect the intracellular assembly and/or 
packaging of mucins, regulating their secretion and function [67]. 
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Figure 1.6: The gastric barrier. A multi-tiered gastric barrier combines pre-epithelial, 
epithelial and post epithelial elements. (From Doron Boltin and Yaron Niv, 2014) 
 
1.5.2 Healing of mucosal damage 
Trefoil proteins appear to be a central player in maintaining mucosal 
integrity of the GI tract also through regulation of two important phases of the 
process of epithelium repair: restitution and regeneration [67]. Restitution is 
the process of re-epithelialization of superficial wounds after injury, as a result 
of cell migration of epithelial cells from within the gastric crypts to damaged 
areas. This process is rapid and, in vivo, can be accomplished within 15-60 
min. Regeneration, instead, involves proliferation and differentiation of 
epithelial cells, responsible for self-renewal within days to months. In case of 
more extensive lesions, restitution is supplemented by proliferation because 
additional cells are needed to span the larger damage area, and both 
epithelial and nonepithelial cells are involved in the tissue remodeling. 
After mucosal injury, there is a marked increase of TFFs expression in 
the region adiacent to the lesion. The induction of expression occurs as early 
as 30 minutes and persist for as long as 10 days after damage [67-69]. During 
restitution, trefoil factors act as motogens, stimulating cell migration by 
disruption of cell-cell and cell-substrate adhesion. How this is achieved is not 
clearly understood and much remains unknown on the underlying mechanism 
of TFF-driven restitution.  
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1.5.2.1 Cell migration 
 
Cell migration involves co-ordinated and dynamic changes in the actin 
cytoskeleton and cell adhesion, with a continuous assembly and disassembly 
of cell–ECM or cell–cell contacts and constant remodelling of the associated 
actin cytoskeleton. Adherens junctions initiate and maintain cell-cell contacts, 
composed of the transmembrane protein E-cadherin and intracellular 
components, p120-catenin, β-catenin and α-catenin. Disruption of adherens 
junctions requires loss of E-cadherin/β-catenin complex with β-catenin 
tyrosine phosphorylation. TFFs appear to induce β-catenin phosphorylation, 
with consequent dowregulation of adhesion molecules as E-cadherin [67, 70-
72]. The cell migration requires also the dissociation of cell-substrate 
contacts. Focal adhesions are sites where integrin and proteoglycan mediated 
adhesion links to the actin cytoskeleton. TFFs are capable of induce 
dissociation of the focal adhesion complex by phosphorylation of focal 
adhesion kinase (FAK), resulting in the disruption of focal adhesions between 
a cell and its substratum [67].   
Furthermore, TFFs work synergistically with other growth factors and 
epithelial cytokines implicated in signalling pathways that promote mucosal 
healing. In particular, also transforming growth factor-β (TGF-β) is a potent 
activator of chemotaxis and the EGF receptor (EGF-R) is associated with E-
cadherin/β-catenin complex: TFFs seem to work independently from TFG-β 
and in synergy with EGF on cell migration [73, 74].  
Rho-family GTPases regulate cytoskeletal changes and are 
considered to be initiating signals for cell migration. The GTP-binding proteins 
Rho, Rac and Cdc42 are known to regulate actin organization [75]. Several 
studies have shown that trefoil peptides may activate Rho-family members 
(fig. 1.7) [76]. 
 
 
1.5.2.2 Cell survival signaling 
 
In the process of epithelial restitution, the epithelial cells, having to 
migrate to cover the denuded damaged area, are vulnerable to apoptosis or 
anoikis, which is the form of apoptosis that is induced by anchorage-
dependent cells detaching from the surrounding extracellular matrix. 
Therefore, anti-apoptotic properties are very important to inhibit anoikis and 
promote cell survival. Trefoil factors have been found to have anti-apoptotic 
effects in several cell lines. In particular, TFF1 was found to protect cells from 
three different types of induced apoptosis by partially or completely blocking 
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caspase-3, -6, -8 and -9 activities [77]. TFFs also regulate cell survival via 
ERK/MAPK, PI3K/Akt, phospholipase C (PLC)/PKC, β-catenin, and EGF 
signaling pathways (fig. 1.7) [78-82]. It has been shown that TFF3 has 
antianoikic effects on intestinal epithelial cells via activation of NF-kB [83] and 
TFF3-deficient mice have increased numbers of apoptotic cells in the colonic 
crypts [84].  
 
 
Figure 1.7: Candidate TFF pathways in epithelial repair. TFF peptides facilitate GI 
epithelial restitution by stimulating cell migration and inhibiting apoptosis of 
the migrating cells. (From Aihara E., Engevik K. A., and 
Montrose M. H., 2016) 
 
 
1.5.2.3 Pro-angiogenic activity 
 
Repair of mucosal injury also requires angiogenesis, the formation of 
new microvessels, when deeper lesions in the GI tract occur. 
Angiogenesis facilitates nutrient and oxygen delivery to the injured 
area, thus allowing fibroblasts proliferation. Vascular endothelial growth factor 
(VEGF) and fibroblast growth factor (FGF) are both strong angiogenic factors 
for vascular endothelial cells. In vivo and in vitro experiments demonstrated 
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that TFFs have proangiogenic properties and induce responses comparable 
to those observed with the classical angiogenic factors [85]. Angiogenesis 
induced by TFF1 was demonstrated to be dependent on both 
cyclooxygenase-2 (COX-2) and EGF-R signaling [85]. 
 
 
1.5.2.4 Immune modulation 
  
Epithelial damage with disruption of the mucosal barrier also creates 
an inflammatory status. Thus, efficient repair is important in re-establishing 
homeostasis and suppressing mucosal inflammation. The inflammatory 
response is associated with an early recruitment of neutrophils that secrete 
antimicrobial agents such as proteases, chemokines, and cytokines, which 
also control the subsequent recruitment of monocytes that differentiate into 
macrophages in the wound bed. Endogenous proresolving proteins/peptides 
and lipid mediators released by a number of cell types orchestrate the 
resolution of inflammation and wound repair.  
Many studies showed that TFFs may have direct effects on the inflammatory 
response [86]. TFFs are regulated by both pro-inflammatory [87] and anti-
inflammatory cytokine expression [88–90], and have been postulated to 
participate in the mucosal immune response by stimulating immunocyte 
migration [91]. 
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CHAPTER 2 
 
TFF1 AND CANCER  
 
2.1 Introduction 
In recent years clinical and experimental studies showed that TFFs, in 
addition to the protective function in the gastrointestinal tract, have also 
crucial roles in cancer development and progression. Aberrant expression of 
TFFs genes and proteins in humans have been reported for a wide range of 
solid tumours. TFF1 is mainly associated with gastric cancer and breast 
cancer, but changes in its expression levels have also been described in 
pancreatic, lung, prostate and colorectal cancer. However, the role of trefoil 
proteins in cancer has not been fully understood.  
Reading the current literature, a dual role arises for TFFs, presented 
as tumor suppressor genes and tumor progression factors. This apparent 
contradiction in their mode of action in the tumor environment comes from 
different evidence according also to the type of cancer considered. Regarding 
TFF1, in some malignant processes a downregulation of its expression is 
described because of deletions, mutations or methylation of its gene. In 
others, an induction of TFF1 expression is described, with subsequent 
stimulation of cell survival, migration and invasion processes, promoting 
tumor dissemination. 
 
 
2.2 TFF1 in gastric cancer 
2.2.1 Gastric cancer 
Gastric cancer (GC) is the third most common cause of cancer-related 
death in the world [92]. Genetic basis, environmental and nutritional factors 
have been implicated in the development of the disease: diet, tobacco and 
also Helicobacter pylori infection have been associated with increased risk of 
developing gastric cancer. 
Gastric adenocarcinomas are classified according to prognosis into 
two main groups: early and advanced. Histologically the most frequently used 
system is the Lauren classification, which recognizes two main histologic 
subtypes: intestinal type and diffuse type (fig. 1.8) [93]. The intestinal subtype 
is the most frequently diagnosed in older individuals, males more than 
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females, strongly associated with H. pylori infection and is characterized by 
malignant epithelial cells that show cohesiveness and glandular differentiation 
infiltrating the stroma [94]. The diffuse subtype is more aggressive, generally 
diagnosed in younger patients and is more frequently associated with loss of 
E-cadherin expression [94, 95]. This tumor is composed of cells with little 
cohesiveness that tend to invade the gastric wall and adjacent structures. A 
variant of the diffuse type is the signet ring cell adenocarcinoma, 
predominantly composed (>50%) of signet ring cells characterized by 
abundant cytoplasmic mucin that displaces the nucleus to the periphery [96]. 
 
 
Figure 1.8: Hystologically classification of gastric cancer. A, Intestinal type 
carcinoma. B, diffuse-type carcinoma composed of signet-ring cells showing foamy 
cytoplasm and an eccentrically located nucleus.  
 
 
2.2.2 TFF1 as tumor suppressor in GC 
The first evidence of a role of TFF1 in the neoplastic processes came 
from the engineering of the TFF1-/- mouse, which showed marked hyperplasia 
and dysplasia, antral/pylorus-specific adenoma and, in 30% of cases, 
multifocal intraepithelial or intramucosal carcinoma [97]. Furthermore, despite 
the high sequence homology and structural similarity, the TFF2 and TFF3 
knock-out mice don‘t develop cancer, indicating that these peptides do not 
have the characteristics of tumor suppressors [98, 99]. These data have 
demonstrated the importance of TFF1 for normal differentiation of 
antral/pylorus gastric mucosa and its role as tumor-soppressor in the gastric 
tissue.  
During the years, numerous studies have reported that reduced TFF1 
expression levels are associated with most gastric cancers (about 50%) when 
compared with the surrounding normal mucosa [34, 100-103]. Loss of TFF1 
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expression has been associated with the intestinal and atypical histological 
sub-types and with loss of differentiation [34-36, 41, 100, 104-106]. The low 
expression or absence of TFF1 in GC is due to genetic alterations as gene 
mutations and loss of heterozygosity (LOH). In 16% of gastric cancers from 
Korean population were found somatic missense mutations in exons 1 and 2 
of TFF1 [107], but no mutations of TFF1 have been identified in a study on 90 
European patients with GC [108]. Carvalho et al [108] described loss of 
heterozygosity and promoter methylation, but not mutations of TFF1.  
Epigenetic changes are another important mechanism of regulation of 
TFF1 expression in human gastric cells. In N-methyl-N-nitrosourea-induced 
gastric carcinogenesis mouse model TFF1 silencing is achieved by histone 
modifications, as H3K9 methylation and H3 deacetylation at its promoter 
[109]. The hypermethylation status of the promoter CpGs, down-regulates 
TFF1 levels and appeared to be correlated with tumor formation at early 
stages of gastric carcinogenesis [102, 108, 110]. Feng and coworkers found 
methylated sites among three CmCGG (cytosine-methylcytosine-guanine-
guanine) sequences: −354, −84 and −2 nt, particularly in −354 [111]. 
 
 
2.2.3 TFF1 as oncogenic factor in GC 
In the same way, several studies highlight cancer-promoting actions of 
TFF1. Immunohistochemically TFF1 is detected in 66.7% of gastric carcinoma 
cases and a significant association between immunohistochemical TFF1 
expression and diffuse-type GC has been revealed [36]. TFF1 mRNA has 
been detected in hyperplastic polyps, in 50% of human gastric cancers and in 
three of seven commonly studied gastric cancer cell lines [103]. TFF1 protein 
is highly expressed in gastric mucosa with atypical hyperplasia, while it is not 
observed in poorly differentiated or intestinal type GC [112, 113]. 
Furthermore, the protein is preferentially expressed in early-onset gastric 
carcinoma as opposed to conventional gastric carcinoma [113, 114]. In 
addition, TFF1 protein expression is increased in gastric carcinoma with nodal 
metastases compared with carcinomas lacking such metastases [103].  
TFF1 was also one of two genes used in a PCR assay to predict 
lymph node micrometastasis in gastric cancer [115]. TFF1 mRNA alone was 
found to be a useful marker for detection of lymph node micrometastasis 
[115]. It has been also reported that TFF1 mRNA is significantly increased in 
scirrhous gastric cancer cells with greater metastatic potential compared with 
their less metastatic counterpart [116]. Increased levels of TFF1 protein seem 
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to independently predict worse outcome, both overall and in resectable gastric 
cancer [117]. 
 
2.3 TFF1 in breast cancer 
Breast cancer is the most common female cancer. Two of the trefoil 
proteins, TFF1 and TFF3, are frequently expressed at high levels in breast 
cancer [104, 118-120]. TFF1 was originally discovered as an oestrogen-
inducible gene in a hormone-dependent breast cancer cell line, MCF-7 [6]. 
The peptide was found overexpressed in approximately 50% of primary 
breast carcinomas [119, 121], mainly in those positive for estrogen receptor 
alpha (ERα+). TFF1 expression is regulated by oestrogen, epidermal growth 
factor (EGF), tumor promoter 12-O-tetradecanoylphorbol 13-acetate (TPA) 
and the proto-oncogenes c-Ha-ras and c-jun.23, through the activation of the 
gene promoter containing an estrogen-response element (ERE) and a TPA-
response element (TRE) [122]. Also TPA and EGF significantly upregulate 
TFF1 gene expression in MCF-7 cells and act in synergy with oestrogen 
[123]. 
Numerous studies evaluated the potential clinical significance of TFF1 
in breast cancer. Considering that only low levels of the peptide have been 
found in normal breast tissue [119], it has been proposed that its 
overexpression in breast cancer contribute to tumor aggressiveness. TFF1 
appears to work as oncogene, stimulating cell proliferation [17], migration, 
anchorage-independent growth, invasion and/or angiogenesis processes of 
breast cancer cells [124-126]. Furthermore, TFF1 is also an informative 
marker for the detection of micrometastases [127], being expressed in 
metastases derived from TFF1-positive primary tumors [128] and strongly 
correlated with breast cancer bone metastases [129].  
Despite numerous studies, TFF1 physiopathological functions remain 
controversial. Numerous data have also suggested a beneficial role of TFF1 
expression in human breast cancers. Transgenic mice expressing TFF1 in 
their mammary glands do not show increased cell proliferation or tumor 
formation [130]. Moreover, it is considered a potent marker of hormone-
dependent breast tumors and of hormone-therapy responsiveness [131-135].  
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2.4 TFF1 in prostate cancer 
Prostate cancer (PC) is a major cause of cancer morbidity and 
mortality in the western world. TFF1 mRNA and protein are differentially 
expressed between human benign and malignant tissues, with 92% of 
prostate cancers positive for TFF1 [136, 137]. Bonkhoff and coworkers [136] 
showed that TFF1, in prostate cancer, is closely associated with premalignant 
changes and neuroendocrine differentiation. Additionally, plasma levels of 
TFF1 are increased in patients with advanced prostate cancer and the highest 
concentrations are found in patients with bone metastases [138]. It has been 
found that promoter hypomethylation of TFF1 is closely associated with 
increased expression of the gene [139]. Furthermore, forced expression of 
TFF1 in prostate cancer cells revealed the capability of this protein to promote 
migration and invasion in vitro and a mesenchymal phenotype through down-
regulation and cellular re-distribution of the epithelial marker E-Cadherin 
[140]. 
 
 
2.5 TFF1 in colon cancer 
TFF1 is absent in normal colon mucosa but is induced at high levels in 
Crohn disease and colorectal cancers [80]. 
TFF1 protein has found to be expressed in 89% of colorectal 
carcinomas [141] and in 60% of primary colorectal carcinomas [142]. Another 
study reported that TFF1 protein expression in colorectal carcinoma is 
correlated with heat-shock protein 70 (HSP70) expression and also with 
incomplete surgical resection of the tumour, suggesting that it may be related 
to invasive tumor behavior and may also play a role in tumor recurrence [143]. 
Rodrigues and collaborators have also demonstrated that TFF1 stimulated 
colorectal adenocarcinoma progression in vitro and in vivo by promotion of 
cell survival, anchorage independent growth and conferment of an invasive 
phenotype [144]. It was shown that TFF1 may be involved in the neoplastic 
progression of colon epithelial cells at two levels, namely the adenoma-
carcinoma transitions and in established adenocarcinoma cells [144]. 
  
 
2.6 TFF1 in other cancers 
The expression of the trefoil factors has been described in a variety of 
solid tumors.  
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TFF1 is widely expressed in cancerous but not in normal pancreatic 
cells [145-147]. It is expressed early in preneoplastic cells and also in 
advanced cancer cells and increases pancreatic cancer cell invasion, but not 
proliferation, promoting the aggressiveness of cancer [148].  
It has also been reported that TFF proteins are related to lung cancers 
[149-151]. TFF1 levels are increased in serum of patients with lung cancer 
and reduced after tumour resection [152], and positive expression of TFF1 
indicates worse prognosis of lung cancer [153].  
TFF1 is aberrantly expressed also in biliary and hepatocellular 
carcinomas [154-156]. In mucinous ovarian cancer development, TFF1 plays 
an oncogenic role, and its high expression predicts a poor clinical outcome 
[157]. In addition, TFF1 was the only TFFs peptide expressed at detectable 
levels in immunoblots of retinoblastoma cells [159].  
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CHAPTER 3 
 
TFF1 AND COPPER 
 
3.1 Copper: biological role and homeostasis 
Copper (Cu) is a transition metal and a micronutrient essential for life. 
In cells, it is present in two redox states, oxidized Cu(II) and reduced Cu(I). It 
is important for many cellular processes such as respiration, iron transport, 
oxidative stress protection, peptide hormone production, pigmentation, blood 
clotting and normal cell growth and development. Copper is able to work as a 
catalytic cofactor of a variety of proteins and ligands involved in electron 
transfer reactions and in redox reactions: Cu-containing biological molecules 
react directly with molecular oxygen, to produce free radicals, which can 
cause catastrophic damage to lipids, proteins and DNA [160, 161]. It is 
essential to guarantee copper homeostasis to avoid its unwanted and 
uncontrolled reactions that can cause damages. 
Cells have developed dedicated components and sophisticated 
homeostatic mechanisms to acquire and maintain adequate intracellular Cu 
concentrations. A network of evolutionary conserved Cu transporters and 
metallo-chaperones bind and shuttle the metal to ensure proper delivery in 
various cellular organelles and compartments [161, 162]. 
Humans uptake copper primarily from the consumption of food and drinking 
water. About 50% of the average daily dietary copper of around 25 μmol (1.5 
mg) is absorbed from the stomach and the small intestine, transported to the 
liver in portal blood and transferred to peripheral tissues mainly bound to 
ceruloplasmin and, to a lesser extent, albumin. Bile is the major pathway for 
the excretion of copper and the faecal copper output results from biliary 
excretion. 
Cu homeostasis is regulated by alterations in both the absorptive 
efficiency and biliary excretion in the gut. At low and high intakes, the 
efficiency of absorption is regulated up and down, respectively, but is 
predominantly controlled via endogenous excretion. 
Intestinal copper uptake is performed by Ctr1. It is a high affinity 
copper transporter Ctr1, first identified in yeast [163], which is expressed in all 
cell types and catalyzes the transport of Cu(I) across the cell membrane 
[164]. The divalent metal transporter 1 (DMT1) is important for iron 
homeostasis but it seems to mediate the transport of several metal ions, 
including copper [165, 166]. Upon entry into the cell, copper binds to cytosolic 
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copper chaperones (CCS) and Atox1, which then deliver it to intracellular 
proteins and compartments. CCS incorporates copper into the cytosolic 
protein Cu,Zn-SOD (Cu,Zn-superoxide dismutase), Atox1 delivers copper to 
the Cu-transporting ATPases, ATP7A and ATP7B. ATP7A is expressed in 
many tissues except the liver, instead ATP7B is mainly present in the liver 
and in neuronal tissues. Normally, these proteins transport copper into the 
lumen of the Golgi, where the metal can be incorporated into copper-
dependent proteins, but when intracellular copper concentration is elevated 
ATP7A moves to the plasma membrane promoting copper efflux while ATP7B 
mobilizes excess Cu into the bile.  
Copper must also be targeted to mitochondria, where cytochrome c 
oxidase (CCO) uses copper for oxidativephosphorylation. In mitochondria 
Cox17, Cox11, Sco1 and Sco2 are the proteins involved in copper insertion 
into CCO.  
 
 
Figure 1.9: Schematic copper distribution pathways in mammalian cell.  
(From Lutsenko S., 2010) 
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3.2 Copper and human diseases 
 
Copper imbalance in humans lead to serious damages and diseases. 
Excessive levels of copper can result in liver and kidney damage, 
anemia, immunotoxicity, and developmental toxicity [167]. An excess of Cu 
could result in oxidative-stress-related health disorders, given the capacity of 
copper to produce large amounts of reactive oxygen species (ROS) that can 
create oxidative damage to membranes or macromolecules.  
Cu deficiency also affects, directly or indirectly, the components of the 
oxidant defense system. 
Menkes syndrome and Wilson disease are genetic disorders, resulting 
from the absence or dysfunction of copper-transporting ATPases and 
characterized by the inability to appropriately distribute copper to all cells and 
tissues. Menkes disease is an X-linked recessive disease, charactherized by 
a profound systemic copper deficiency because of defects in the gene that 
encodes the copper-transporting ATPase ATP7A. Most affected individuals 
die before the age of 10 years [168]. Wilson disease is an autosomal 
(chromosome 13) recessive inherited disorder of copper transport, induced by 
genetic defect in ATP7B gene. The pathology is characterized by excessive 
copper accumulation, predominantly in liver and brain and, to a lesser extent, 
in eyes, kidneys, and other organs, because of impaired biliary copper 
excretion. Wilson disease onset from 3 to 50 years and the clinical outcomes 
vary widely [169]. 
Additionally, copper has been strongly implicated in 
neurodegenerative diseases such as familial amyotropic lateral sclerosis 
(FALS), Alzheimer's disease, and prion diseases of neuronal spongiform 
encephalopathy [170]. 
 
 
3.2.1 Copper and cancer 
 
Copper has been shown to play a significant role in cancer. Several 
studies have shown significantly elevated copper levels in both serum and 
tumor tissue of cancer patients. Copper is implicated in several important 
processes for tumoral development and growth. In particular, copper 
promotes angiogenesis, regulating directly or indirectly numerous 
angiogenesis-related factors e.g. VEGF, basic fibroblast growth factor 
(bFGF), tumour necrosis factor alpha (TNF-α) and interleukin (IL) 1 [171, 
172]. In this way, it stimulates endothelial cells proliferation and migration. 
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Copper has also a central role in oxidative stress and resulting 
genome instability or DNA damages. Furthermore, copper ions regulate 
factors involved in tumor cell motility and invasiveness. Several Cu- 
dependent proteins have been reported to promote tumor cell migration and 
invasiveness. The copper-dependent amine oxidase lysyl oxidase (LOX) 
stimulates cell invasion, migration and tumor progression in many 
malignancies [173, 174]. Lysyl oxidase-like 2 (LOXL2), a member of the LOX 
protein family, is overexpressed in gastric cancer and is involved in gastric 
cancer invasion [175]. Parr-Sturgess and coworkers demonstrated that 
copper modulates zinc metalloproteinase-dependent ectodomain shedding of 
the Notch ligand Jagged1 and the adhesion molecule E-cadherin and 
promotes the invasion of prostate cancer epithelial cells [176]. Recently it has 
been reported that also the copper chaperone Atox1 plays a role in breast 
cancer cell migration [177]. 
Copper chelation is a new useful strategy for treating cancer. Copper-
specific chelators have been developed as therapeutic agents to inhibit 
neoplastic processes. Copper chelators such as D-penicillamine [178], 
tetrathiomolybdate [179], clioquinol [180], and trientine [181] have been 
shown to inhibit angiogenesis both in vitro and in vivo. Penicillamine and 
tetrathiomolybdate are being described in the literature as having also anti-
fibrotic and anti-inflammatory actions [182].  
It has been shown that Cu depletion results in suppression of many 
cell signaling pathways including Hypoxia-inducible factor-HIF-1α, NF-κB, 
ERK, p38, and JNK, among others, leading to inhibition of tumor growth and 
reduced metastasis [183-185]. 
In recent years there has been a rapid expansion in research and 
development of novel metal-based anticancer drugs, including copper 
coordination complexes. These compounds may be more potent than 
conventional platinum-based drugs, with reduced toxicity toward normal cells 
and they may potentially circumvent the chemoresistance associated with 
recurrent platinum treatment [186].  
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Figure 1.9: Mechanism of action of the main copper chelators and coumpounds, 
affecting tumor growth, angiogenesis and metastasis.  
(From Denoyer D., Masaldan S., La Fontaine S., Cater M. A.,  2015) 
 
 
3.3 TFF1-Cu complex 
 
Recently it has been highlighted an interesting structural and 
functional correlation between TFF1 and copper, following the observation of 
an increased expression of the peptide in copper deficient rats [187, 188]. 
Then it has been demonstrated that the monomeric form of TFF1 is able to 
selectively bind copper ions [187] through its highly acidic carboxy-terminus, 
with a 1:1 stoichiometry of complexation [188]. The Cys58 residue and the 
four glutamic acid residues around it are essential for the interaction. 
Furthermore, copper induces conformational changes in the tertiary structure 
of the protein, resulting in a greater stability and higher proteases resistance. 
In addition, it promotes homodimer formation and increases its motogenic 
activity [187, 189]. The homodimeric form of TFF1 is also capable to bind Cu. 
Among the other TFFs, TFF3 has a greater structural similarity with TFF1 and 
it has been shown that similarly forms a Cu-complex with a 1:1 stoichiometry 
and no interaction with other divalent cations was detected [190]. 
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 Copper also effects transcriptional regulation of TFF1, through the 
modulated binding of the copper-sensing transcription factor Sp1 onto the 
responsive elements present in the regulatory region of the gene. In 
particular, it has been detected a putative Sp1 binding site 559 bp upstream 
the transcription start site, beyond the already reported Sp1 binding site in 
position −420 bp [191] and it has been demonstrated the direct involvement of 
Sp1 in copper mediated regulation of TFF1gene [190]. 
In addition, Cu levels can influence TFF1 secretion: high copper levels 
reduce protein secretion and also induce an accumulation of TFF1 in the 
Trans-Golgi Network. Moreover, also TFF1 appears to have a role in the 
regulation of copper homeostasis. The peptide can influence copper excretion 
and its induced toxicity, modulating the copper trafficking mechanisms in the 
gastrointestinal tissues [190]. 
 
 
 
                                                                                                             Aim of the work 
 
- 26 - 
 
 
Aim of the work   
 
Trefoil factors play an essential role in the gastric epithelial restitution, 
but in recent years clinical and experimental studies have shown an active 
function of TFFs in the genesis of neoplastic processes.  
TFF1 is associated with a variety of solid tumors, mainly with gastric 
cancer. However, the relationship between TFF1 and gastric cancer is not 
well defined and often contradictory in literature. In addition, the distinct 
signaling pathways that mediate the effects of TFF1 have not been fully 
elucidated, and its functional receptors have not yet been identified.  
Therefore, this work presents as principal aim the investigation of 
TFF1 role in tumor progression. In particular, by using in vitro models, this 
study has the purpose to elucidate the functional roles of TFF1 in human 
gastric cancer, focusing the attention on several aspects of tumor 
development, such as invasion and EMT. 
The project is, moreover, aimed to investigate the influence of copper 
ions on TFF1 functions and to define the signaling pathways of the peptide 
with the identification of possible receptors through which TFF1 exerts its 
action. 
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CHAPTER 4   
 
MATERIALS AND METHODS 
 
4.1 Cell Cultures 
The human gastric cancer cell line AGS and KATO-III were purchased 
from the American Type Culture Collection (CRL-1739; Rockville, MD, USA), 
AGS, a human gastric adenocarcinoma cell line, was cultured in HAM‘S F12 
medium (Euroclone) containing L-Glutamine 2 mM and 10% heat-inactivated 
fetal bovine serum (FBS; Euroclone).  
AGS-AC1 cell line is an AGS cell clone, stably transfected with a 
pUHD-hTFF1 plasmid overexpressing TFF1 in an inducible manner with 
doxycycline. It was kindly provided by Dr. M.C. Rio (IGBMC - Institute de 
Génétique et de Biologie Moléculaire et Cellulaire, Strasbourg, France). AGS-
AC1 cells were maintained in DMEM (Dulbecco's Modified Eagle Medium, 
Euroclone) supplemented with 10% FBS and 600 μg/mL Neomycin (G418, 
Sigma). The expression of TFF1 in this cell line was promoted by adding 
doxycycline (1 μg/mL) to the culture medium.  
KATO-III, a human gastric carcinoma cell line derived from metastatic 
site, was cultured in RPMI 1640 (Euroclone) with 10% heat-inactivated FBS  
(Euroclone).  
ARCaP E cell line is an Androgen Repressed Metastatic Human 
Prostate Cancer Cell Line, purchased from Novicure Biotechnology. This cell 
line was cultured in MCaP medium (Novicure Biotechnology) with 5% FBS. 
All the media were supplemented with antibiotics (10000 U/mL 
penicillin and 10 mg/mL streptomycin; Euroclone). Cell lines were grown at 
37°C in 5% CO2 and 95% air humidified atmosphere. 
 
4.2 Hypoxic culture condition 
Hypoxic culture condition was obtained by incubating cells in tissue 
culture dishes in a modular incubator chamber (Billups-Rothenberg Inc.) 
flushed with a gas mixture containing 5% CO2 and 95% N2 at 37°C.  
In some cases, the hypoxic condition was created by treating cells with 
the chemical inducer of hypoxia, cobalt chloride (CoCl2, 200 μM; Sigma 
Aldrich). 
 
CHAPTER 4                                                                             Materials and Methods 
 
- 28 - 
 
Cells were then harvested at different times (from 24 up to 72 hours) 
of treatment and analyzed as described below. 
 
4.3 Western blotting analysis  
Expression of TFF1 was examined by SDS-PAGE. Total intracellular 
proteins were extracted from the cells by freeze/thawing in lysis buffer (Tris 
HCl 20 mM, pH 7,4; sucrose 250 mM; DTT 1 mM; protease inhibitors, EDTA 1 
mM in water). Protein content was estimated according to Biorad protein 
assay (BIO-RAD). Samples (20 µg protein) were loaded onto 10% 
denaturing-polyacrylamide gel and separated by SDS-PAGE. The separated 
proteins were then transferred electrophoretically to nitrocellulose membranes 
(Immobilon-NC, Millipore). Membranes were blocked with 5% non-fat dry milk 
(BioRad) in TBS-Tween (NaCl 150 mM; KCl 3 mM; Tris-HCl 25 mM pH 8, 
0,1% Tween 20) and then incubated overnight at 4°C with the primary 
antibodies. Proteins were visualized using the enhanced chemioluminescence 
detection system (Amersham Pharmacia Biotech) after incubation overnight 
at 4°C with primary antibodies against TFF1 (rabbit polyclonal; 1:500; 
GenScripts Corp), E-cadherin (mouse monoclonal; clone 36/E-Cadherin; 
1:10000; BD Transduction Laboratories), vimentin (mouse monoclonal; clone 
E-5; 1:1000; Santa Cruz Biotechnologies), HIF1-α (rabbit polyclonal; clone 
A300-286A; 1:5000; Bethyl Laboratories), CK8 (mouse monoclonal, clone 
M20; 1:1000; Santa Cruz Biotechnologies), CK18 (mouse monoclonal, clone 
C-04; 1:1000; Santa Cruz Biotechnologies), β-actin (mouse monoclonal; 
clone C-4, 1:1000; Santa Cruz Biotechnologies), GAPDH (mouse monoclonal; 
1:1000; Santa Cruz Biotechnologies) and then at room temperature with an 
appropriate secondary rabbit or mouse antibody (1:5000; Sigma-Aldrich). 
Immunoreactive protein bands were detected by chemioluminescence using 
enhanced chemioluminescence reagents (ECL; Amersham). The blots were 
exposed to Las4000 (GE Healthcare Life Sciences) and the relative band 
intensities were determined using ImageQuant software (GE Healthcare Life 
Sciences). 
 
 
4.4 Confocal Microscopy 
After the specific time of incubation, AGS and AGS-AC1 cells were 
fixed in p-formaldehyde (4% v/v in PBS) for 5 minutes. The cells were 
permeabilized in Triton X-100 (0.5% v/v in PBS) for 5 minutes, and then  
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incubated in goat serum (20% v/v PBS; Lonza) for 30 minutes, and with rabbit 
anti-TFF1 antibody (1:500; Life Span Biosciences), mouse anti-E-cadherin 
(1:1000; BD Transduction Laboratories), mouse anti-vimentin (1:500; Santa 
Cruz Biotechnologies), mouse anti-CK8 and anti-CK18 (1:1000; Santa Cruz 
Biotechnologies) overnight at 4°C. After two washing steps with PBS, cells 
were incubated with anti-rabbit and/or anti-mouse AlexaFluor (488 and/or 
555; 1:1000; Molecular Probes) for 2 hours at RT. The coverslips were 
mounted in Mowiol (Mowiol 4-88, Sigma-Aldrich). A Zeiss LSM 710 Laser 
Scanning Microscope (Carl Zeiss MicroImaging GmbH) was used for data 
acquisition. To detect nucleus, samples were excited with a 458 nm Ar laser. 
A 488 nm Ar or a 555 nm He-Ne laser was used to detect emission signals 
from target stains. Samples were vertically scanned from the bottom of the 
coverslip with a total depth of 5 μm and a 63X (1.40 NA) Plan-Apochromat oil-
immersion objective. Images and scale bars were generated with Zeiss ZEN 
Confocal Software (Carl Zeiss MicroImaging GmbH) and presented as single 
stack. Images were processed using ImageJ software (NIH), Adobe 
Photoshop CS version 5.0, and figures assembled using Microsoft 
PowerPoint (Microsoft Corporation). 
 
 
4.5 RNA isolation and quantitative RT-PCR assay 
 
mRNA levels were analysed by Real- time PCR using the Light Cycler 
480 II instrument (Roche). Total RNA was extracted from cultured cells using 
Tripure Isolation Reagent® (Sigma), quantized with the instrument NanoDrop 
1000 (Thermo Scientific) and its integrity was checked by electrophoresis on 
1.3% agarose gel. 1µg of total RNA was reverse transcribed into cDNA with 
M-MLV Reverse Transcriptase kit (Sigma). 5 µl of 1:10 diluted cDNA were 
used in a 20 µl reaction using StoS Quantitative Master Mix 2X SYBR Green 
(GeneSpin) Cycling conditions for amplification were 95°C for 1 min; 35 
cycles at 95°C for 45 s, annealing temperature (varing from 58°C to 60°C) for 
30 s, and 72°C for 30 s; finally, 72°C for 5 min. Quantitative measurements 
were determined using the comparative ΔΔCt method. 
Primer sequences used in this study are indicated below. 
 
Oligo name Forward (5‘-3‘) Reverse (5‘-3‘) T °C 
VIMENTIN CTCCGGGAGAAATTGCAGGA TTCAAGGTCAAGACGTGCCA 60 
N-CADHERIN TGTTTGACTATGAAGGCAGTGG TCAGTCATCACCTCCACCAT 60 
E-CADHERIN TTCCCAACTCCTCTCCTG AAACCTTGCCTTCTTTGTC 58 
CK18 AATGGGAGGCATCCAGAACGAGAA TTCTTCTCCAAGTGCTCCCGGATT 60 
TWIST GCCAGGTACATCGACTTCCTCT TCCATCCTCCAGACCGAGAAGG 56 
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SNAIL TGCCCTCAAGATGCACATCCGA GGGACAGGAGAAGGGCTTCTC 60 
NANOG CAGTCTGGACACTGGCTGAA CTCGCTGATTAGGCTCCAAC 60 
ZEB1 GCCAATAAGCAAACGATTCTG TTTGGCTGGATCACTTTCAAG 60 
FPR1 CTGAGTCACTCTCCCCAGGA CCAGGAAGAGATAGCCAGCA 58 
FPR2 CTGGCTACACTGTTCTGCGG GAGGTTGATGTCCACCACGA 60 
FPR3 GCCGTCCCTTACGTGTCTTC ATTGGGTTGAGGCAGCTGTT 60 
HPRT1  GACCAGTCAACAGGGACAT CCTGACCAAGGAAAGCAAAG 60 
 
Table 4.1: Primer sequences used for RT-PCR. 
 
  
4.6 Matrigel Invasion Assay 
AGS and AGS-AC1 invasiveness was studied using the Trans-well 
Cell Culture (12 mm diameter, 8.0-μm pore size) purchased form Corning 
Incorporated (USA). The chambers were coated with Matrigel (Becton 
Dickinson Labware) that was diluted with 3 volumes of serum-free medium 
and stored at 37°C until its gelation. Cells were plated in 350 μl of serum-free 
medium at a number of 9 x 104/insert in the upper chamber of the trans-well. 
1,4 ml of medium with FBS were put in the lower chamber and the trans-well 
was left for 24 hours at 37°C in 5% CO2 - 95% air humidified atmosphere. 
After that, the medium was discarded, the filters were washed twice with PBS 
and fixed with 4% p-formaldehyde for 10 minutes, then with 100% methanol 
for 20 minutes. So fixed filters, were stained with 0.5% crystal violet prepared 
from stock crystal violet (powder, Merck Chemicals) by distilled water and 
20% methanol for 15 minutes. After that, the filters were washed again in PBS 
and cleaned with a cotton bud. The number of cells that had migrated to the 
lower surface was counted in twelve random fields using EVOS light 
microscope (10X) (Life technologies Corporation). 
Treatments with chemical compounds and conditioned media were 
done in the lower chamber.  
 
 
4.7 Gelatin zymography  
 
AGS-AC1 cells were grown to approx 80% confluence in complete 
growth media, then washed with sterile PBS and incubated with serum-free 
media at 37°C for 24-48-72 hours. After that, the conditioned media were 
collected, centrifuged (400g, 5 min at 4°C), to remove cells and debris, and 
concentrated 10 times using Amicon centricon-10 concentrators (Amicon) 
Then samples were resolved on a 10% nondenaturing polyacrylamide gel 
containing 1 mg/mL gelatin (Sigma-Aldrich) at 125 V for 1 hour.  
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The resolved gels were soaked in 2.5% v/v Triton X-100 in distilled 
H2O for 30 minutes, rinsed with distilled H2O and then developed at 37°C 
overnight in 500 mM Tris-HCl, pH 7.8; 2 M NaCl and 50 mM CaCl2. Gels were 
stained with Coomassie Blue R 250 (Bio-Rad; 0.5% Coomassie blue R-250 in 
5% methanol, and 10% acetic acid in dH2O) for 1 h and destained with 10% 
methanol, 5% acetic acid in distilled H2O until areas of gelatinolytic activity 
appeared as clear sharp bands over the blue background. Gels were 
photographed using Las4000 (GE Healthcare Life Sciences) and the relative 
band intensities were determined using ImageQuant software (GE Healthcare 
Life Sciences). 
 
 
4.8 Luciferase assays 
 
AGS and AGS-AC1 cells were seeded in a 24-well plate at a number 
of 8 x 104/well and after 24h were transfected using Lipofectamine 2000 
reagent (Invitrogen) according to the manufacturer‘s protocol. The cells in 
each well were transfected with 0.2 μg of pGL3 commercial plasmid 
(Promega) containing different fragments of TFF1 promoter sequence 
upstream of a Luciferase reporter gene. The pGL3 constructs were 
assembled by Sandro Montefusco during his PhD project. Briefly, a region of 
of about 1 kb (1036bp) upstream of TFF1 gene was amplified by PCR on 
genomic DNA extracted from breast cancer cells (MCF-7). The fragment 
obtained was cloned into the pGL3 vector obtaining the pGL3(-1036)Luc. 
Later, sequential deletions by Bal31 exonuclease digestions were performed 
obtaining the subsequent plasmids: pGL3(-830)Luc, pGL3(-583)Luc and 
pGL3(-212)Luc. 
A β-galactosidase control vector (Promega) (0.1 μg/well) was also 
transfected for standardization. Six hours after transfection, the medium was 
replaced and AGS-AC1 cells were induced with doxycycline. 48h after 
transfection, AGS-AC1 cells were incubated in presence or absence of 200 
μM CoCl2 (Sigma Aldrich) and AGS cells with 0-4 μg/mL of TFF1 recombinant 
protein (hrTFF1, Raybiotech). Twenty-four hours after the addition of the test 
agents, cells were lysed and reporter gene assay was performed. The 
luciferase activity was measured using the Luciferase/beta-Galactosidase 
Luciferase Assay Kit, Dual-Light (Applied Biosystems), according to the 
manufacturer‘s instructions. The analysis was performed in quadruplicate and 
the results are reported as the ratio of firefly luciferase activity and beta-
galactosidase (transcriptional activity relative). The light emission was 
measured with EnSpire Multimode Plate Reader (PerkinElmer).  
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4.9 High Resolution Melting (HRM) analysis 
 
Genomic DNA was purified from cells with NucleoSpin® Tissue kit 
(Macherey Nagel) and quantized with NanoDrop 1000 (Thermo Scientific). 
DNA (0.5 μg) was bisulfite modified with EZ DNA Methylation™ kit (Zymo 
Research, Irvine, CA, USA). Sequence-specific primers to amplify the CpG-
rich regions of interest were designed using a computer program and 
analyzed with OligoAnalyzer 3.1 (https://eu.idtdna.com/calc/analyzer). The 
primers used for amplification were as follows: 
 
 TFF1 forward, 5‘-GATTTTTTAGTTAAGATGATTTTATTATATG-3‘  
 TFF1 reverse, 5‘-ATTTTATAAAACAAACTCTATTTACTTAAAA-3′   
The bisulfite-treated DNA was amplified using primers, which 
specifically amplify the methylated or unmethylated sequence of TFF1 
promoter, respectively. Primers have been designed in a region of 
approximately 1kb (from 303 to 703) around the transcription start site on the 
promoter of TFF1 and the amplicon contained 3 CpG in a region of about 200 
bp.The reactions were prepared with LightCycler® 480 High Resolution 
Melting Master kit (Roche) by mixing: Master Mix 1x-2 mM MgCl2 (containing 
FastStart Taq DNA polymerase, reaction buffer, dNTP, High Resolution 
Melting Dye), 400 nM of each primer, 1 μl of modified DNA with bisulfite 
(theorical concentration 25 ng/μl). The amplification and melting analyzes 
were performed with the Light tool Cycler 480 II. PCR comprises a step of 10 
min at 95°C, followed by 45 cycles of 10 sec at 95°C, 10 sec at the annealing 
temperature of 52°C and 15 sec at 72°C. The analysis of high resolution 
melting were performed at increasing temperatures from 65 to 95°C with an 
increase of 0.02°C/s. The melting curves were normalized with LightCycler® 
480 Gene Scanning Software. HRM methylation profiles were compared to 
that of DNA samples with known percentage of methylation (0, 25, 50, 75, 90, 
100), obtained by suitably mixing DNA from MCF-7 as 0% and CpG 
Genome™ Universal Methylated DNA (Millipore) as 100% after being 
modified with bisulfite. 
 
 
4.10 Statistical analysis 
 
All results are the mean ± SD of at least 3 experiments performed in 
triplicate. The optical density of the protein bands detected by Western 
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blotting was normalized against GAPDH or β-actin levels. Statistical 
comparisons between groups were made using unpaired, two-tailed t-test 
comparing two variables. Differences were considered significant if p<0.05 
and p<0.01. 
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CHAPTER 5 
 
RESULTS  
 
5.1 TFF1 expression in GC cell lines  
A variety of gastric carcinoma cell lines have been used as in vitro 
systems. In this study, we used three GC cell lines: a metastatic gastric cell 
line KATO-III, a non metastatic gastric cell line AGS and a stable AGS cell 
clone transfected with pUHD-hTFF1 vector, AGS-AC1. 
These cell lines are different each other for origin, phenotype and 
genotype and also for TFF1 expression. KATO-III cells show a gastric 
phenotype and express high levels of TFF1, instead AGS cells have an 
intestinal phenotype with constitutively low levels of TFF1, undetectable by 
Western blotting under the experimental conditions used.  
The stable clone AGS-AC1 was obtained by transfection of AGS cells 
with an expression vector for TFF1 equipped with a doxycycline inducible 
promoter. 
Western blotting analysis in figure 5.1 showed TFF1 expression in all 
cell lines. KATO-III cells and AGS-AC1 cells induced with doxycycline express 
high levels of TFF1 intracellular and secreted in the supernatants. 
 
 
 
Figure 5.1: TFF1 expression in KATO-III, AGS and AGS-AC1 cells by Western blot 
with anti-TFF1 antibody. TFF1 expression in AGS-AC1 cells was induced with 
doxycycline 1 μg/mL. Protein normalization was performed on GAPDH level. 
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5.2 TFF1 promotes invasive activity of AGS-AC1 cells 
The trefoil factors exhibit a motogenic acitivity and there is a general 
consensus regarding their role in cell migration. Previous studies 
demonstrated, by means of wound healing assays, that increased TFF1 
expression, induced by doxycycline in AGS-AC1 cells, produces an 
appreciable increase in cell migration. This increased migration confirmed the 
cell motogenic activity of TFF1 [189]. 
The acquired capability of tumor cells to migrate and invade 
neighboring tissues is associated with high metastatic potential and advanced 
stage of cancer. To investigate the role of TFF1 in the invasion process, we 
performed matrigel invasion assays on AGS-AC1 cells induced or not with 
doxycycline. The assays were performed at 48h from the induction and 
observed for 24h. Figure 5.2 shows invasion data of AGS-AC1 cells 
expressing or not TFF1, setting 100% the mean values of not induced cells. 
AGS-AC1 induced cells showed significantly increased capacity to invade the 
Matrigel coating, compared with not induced cells. 
 
 
Figure 5.2: Invasion of AGS-AC1 gastric cancer cell lines through Matrigel. 
Upper panel, bottom surface of filters stained with crystal violet. Lower panel, 
quantification of invasive cells. Statistically significant differences at p<0.001 from the 
controls are indicated (***). 
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5.3 Copper deprivation abolishes TFF1 invasive activity 
As stated in the introductive chapter, TFF1 selectively binds copper 
ions [187] through its carboxy-terminal tail and copper levels can modulate its 
biological activity influencing the TFF1 monomer/homodimer ratio [188]. 
Moreover copper is able to enhance the TFF1 induced migration in the AGS 
hyper-expressing clone, probably favouring its homodimerization [188]. 
To further investigate the copper influence on TFF1 functionality, we 
analysed the effect of the metal on TFF1 invasive activity. Therefore, we 
performed invasion assays on the AGS-AC1 clone in presence of copper (10 
μM CuCl2) and/or of the chelating agent bathocuproine (BCS), a non-cell-
permeable chelator of Cu(I).  
The induction of TFF1 expression with doxycycline, as expected, 
increased the cell invasiveness in untreated cells, while in presence of copper 
we had a little increase in the invasion rate in both conditions (induced and 
not). The incubation with the copper specific chelating agent abolished the 
gain of invasion rate. Cells not expressing TFF1 did not show any rate change 
when exposed to BCS. 
The deprivation of copper, obtained by the BCS treatment, reduced 
the increase of invasion of the induced clone (BCS, + dox) to levels 
comparable to the control cultures (not treated, - dox). This result suggests 
that the presence of copper ions can be critical in the performance of TFF1 
invasive function. 
To clarify if it was the reduction in the homodimeric form of the protein 
or the non-formation of the cupro-complex to abolish the invasive activity of 
TFF1, the clone was first grown in the presence of 10 μM CuCl2, so as to 
promote homodimer formation and then, at the time of seeding on matrigel, 
the BCS was added. 
The addition of the chelating agent, to a medium containing the 
dimeric protein, also abolished the increase of invasion, suggesting the 
importance of the TFF1-copper complex formation in the pro-invasive function 
performance (Figure 5.3). 
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Figure 5.3: Invasion of AGS-AC1 gastric cancer cell lines through Matrigel. Induction 
with 1 μg/mL doxycycline, treatment with 500 μM BCS and CuCl2 10 μM. 
 A, bottom surface of filters stained with crystal violet. B, quantification of invasive 
cells. * p<0.05 and *** p<0.001 vs untreated control, $ p<0.05 and $$$ p<0.001 vs 
AGS-AC1 induced cells.  
 
 
5.4 TFF1 hyper-expression stimulates MMP-2 activity   
Cellular invasion process requires proteolytic activity to degrade 
components of the extracellular matrix (ECM). The main group of proteases 
directly associated with metastasis is that of metalloproteases (MMPs), a 
family of endopeptidases capable of cutting various ECM components. In 
particular, the gelatinase MMP-2 (gelatinase A, EC 3.4.24.24) [192] and 
MMP-9 (gelatinase B, EC 3.4.24.35) [193] are two members of the MMP 
family whose expression and activity increase in several tumors and correlate 
with tumor progression [194, 195].  
The gelatin zymography allows to observe the gelatinolytic activity of 
biological samples. It is an electrophoretic technique that includes a substrate 
(gelatin in the case of gelatinase) copolymerized into a polyacrylamide gel for 
the enzymatic activity detection [196, 197].  
To check whether the invasion increase observed following TFF1 
induction was linked to an increase of the metalloprotease activity, we 
performed a zymographic analysis on serum-free medium obtained from the 
AGS-AC1 clone induced or not with doxycycline for 24-48-72 hours. The 
results obtained from the analysis performed by densitometric ImageJ 
software showed an increased gelatinolytic activity of MMP-2 in the AGS-AC1 
clone after 48 hours of induction compared to the control (fig. 5.4). 
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Figure 5.4: A. Gelatin zymography on serum-free media of AGS-AC1 cells, induced 
or not with doxycycline (1 μg/mL) for 24-48-72 hours. B. Densitometric analysis of 
MMP-2 activity, obtained with software ImageJ. 
 
 
5.5 TFF1 secreted in KATO-III supernatant stimulates AGS cell invasion 
The previous invasion assays were performed on the TFF1-inducible 
clone AGS-AC1, obtained from AGS cell line that does not express 
appreciable amounts of the peptide. KATO III cell line, instead, expresses 
high levels of TFF1, detectable by Western Blotting also in the supernatant of 
these cells. In order to evaluate the effects of the secreted TFF1 on a line that 
generally does not express it, and to release ourselves from the unevoidable 
restrictions of a clonal population, we performed further experiments adding 
KATO-III supernatant to AGS cells. As shown in figure 5.5, KATO-III 
supernatant, containing the secreted protein, significantly increased AGS cells 
invasion rate.  
AGS cells were also treated with BCS and the presence of copper 
chelator significantly reversed the increase in the invasion rate of AGS with 
conditioned medium.  
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Figure 5.5: Invasiveness rate of AGS treated with KATO-III supernatant and/or 500 
μM BCS; * p value < 0,01 vs untreated control and $$ p<0.001 vs KATO-III 
supernatant. Invasiveness rates were measured as described in Materials and 
Methods section. Left panel, bottom surface of filters stained with crystal violet.  
Right panel, quantification of invasive cells.  
 
The effect of BCS suggested us that the increase in the invasive 
activity of AGS treated with KATO-III conditioned medium is essentially due to 
secreted TFF1, indicating that TFF1 is able to perform its pro-invasive activity 
in both autocrine and paracrine manner, and that the presence of copper is 
essential for this function. 
 
5.6 Recombinant TFF1 shows pro-invasive activity on AGS cells  
To unequivocably assess the direct effect of extracellular TFF1 on 
cellular invasion, we performed invasion assays on AGS cells using the 
human TFF1 recombinant dimeric protein (hrTFF1). We used three different 
concentrations of hrTFF1 protein and demonstrated its ability to increase in a 
significant and dose-dependent manner AGS basal cell invasion (fig. 5.6).  
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Figure 5.6: Invasiveness rate of AGS treated or not with hrTFF1 protein; * p<0.01 
and ** p<0.001 vs untreated control. Invasiveness rates were measured as described 
in Materials and Methods section. Upper panel, bottom surface of filters stained with 
crystal violet. Lower panel, quantification of invasive cells. 
 
5.7 TFF1 modulates the expression of genes involved in the epithelial- 
mesenchymal transition (EMT) 
Cellular invasion and migration are hallmarks of more aggressive 
tumor cells. EMT is considered as a crucial event in developing invasive 
potential [198]. During EMT, epithelial cells undergo dramatic changes, lose 
their epithelial cell-specific phenotype and develop features of mesenchymal 
cells. 
Through Western blotting, Real Time-PCR and immunofluorescence 
experiments, we wanted to explore whether TFF1 induction in AGS-AC1 cells 
might influence the expression profile of some EMT markers and then to 
determine whether the trefoil factor was able to promote a phenotypic change 
in the cell, directing it toward EMT. 
Data in Figure 5.7 showed that the TFF1 induction was not able to   
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cause a marked phenotypic change in the cells, but certainly prompted them 
towards a phenotypic switching program as evidenced by a slight but 
significant decrease of E-cadherin, key event associated with the destruction 
of the cell-cell junctions and by a cytoskeletal reorganization of vimentin. 
 
 
 
Figure 5.7: A, RT-PCR for Twist, ZEB1, E-cadherin and  N-cadherin mRNA 
expression in AGS-AC1 cells, normalized on HPRT mRNA levels. Statistically 
significant differences at p<0.01 from the non induced cells are indicated (**).  
B, Immunofluorescence analysis of TFF1, E-cadherin, vimentin on AGS-AC1 cells +/- 
doxycycline. Immunofluorescence images refer to 48 hours after induction. Nuclei 
were stained with DAPI. Magnification 63x. Bar = 10 μm. C, Western blot using 
antibodies against TFF1 and vimentin on protein extracts from AGS-AC1 cells. 
Protein normalization was performed on GAPDH levels.  
 
 
To further investigate the role of TFF1 in EMT, we treated AGS cells 
with the TFF1 recombinant protein for 72h, and then the expression of EMT 
markers was evaluated by RT-PCR and immunofluorescence analyses. As 
shown in figure 5.8, hrTFF1 treatment caused a deregulation of a variety of 
proteins and inducers involved in the regulation of EMT. In particular, we had 
a downregulation of epithelial markers, as E-cadherin and Cytokeratin-8 and -
18, and an upregulation of the mesenchymal one, vimentin. In addition to 
these, we also determined the expression levels of transcription factors that 
control the expression of these markers. In particular, TFF1 treatment induced  
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expression of Snail and ZEB1, which are well known repressors of E-cadherin 
expression. Additionally, we registered an upregulation of Nanog, a stemness 
marker.  
 
 
Figure 5.8: Left panel, RT-PCR for TFF1, NANOG, E-cadherin, Snail, vimentin and 
ZEB1 mRNA expression in AGS cells treated or not with hrTFF1 (4 μg/mL) for72h, 
measured on mRNA levels of HPRT in the same experimental models. * p<0.05 and 
** p<0.01 vs untreated control. Right panel, Immunofluorescence analysis to detect 
TFF1, vimentin, Cytokeratin-8 and-18 on AGS cells treated or not with hrTFF1. 
Immunofluorescence images refer to 72 hours after treatment. Nuclei were stained 
with DAPI. Magnification 63x. Bar = 10 μm.  
 
5.8 TFF1 expression and EMT process in hypoxic condition 
Hypoxia, through activation of the transcription factor hypoxia-
inducible factors-1 (HIF-1) is an important stimulus of EMT. 
Interestingly, Hernández and coworkers demonstrated that hypoxia 
inducible factor-1 mediates the induction of TFF gene expression by hypoxia 
in gastric epithelial cells [199]. 
We verified if TFF1 induction is a crucial event that, combined with the 
hypoxic stress condition, can guide cells toward EMT. Hence, we evaluated 
possible alterations of TFF1 expression in AGS cell line exposed to hypoxia 
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for 24 hours. The activation of hypoxia-related pathway was confirmed 
through the detection of a significant increase of HIF1-α induction. We 
observed, furthermore, E-cadherin down-regulation, vimentin up-regulation at 
24 hours of hypoxic treatment as well the TFF1 induction (fig. 5.9). Thus, 
TFF1 upregulation and EMT are concomitant events during the hypoxic 
condition. 
 
 
 
Figure 5.9: A, Western blot using antibodies against HIF-1α, TFF1 and vimentin on 
protein extracts from AGS cells exposed to hypoxia. Protein normalization was 
performed on GAPDH levels. B, Immunofluorescence analysis to detect TFF1 and 
vimentin on AGS cells. Immunofluorescence images refer to 24 hours after hypoxic 
treatment. Nuclei were stained with DAPI. Magnification 63x. Bar = 10 μm.  
C, RT-PCR for TFF1, vimentin and E-cadherin mRNA expression in AGS cells in 
hypoxic condition for 24 h, normalized on HPRT mRNA levels. * p<0.05 and ** p<0.01 
vs normoxic control. 
 
5.9 TFF1 shows an auto-regulation mechanism 
We performed the hypoxic treatment also on AGS-AC1 cells, in order 
to investigate the rate of TFF1 induction at different times from the hypoxic 
stimulus. The Real Time-PCR analysis of TFF1 expression showed, at 48 and 
72 hours of hypoxia in the TFF1-induced cells, particularly eleveted TFF1 
mRNA levels (fig. 5.10). Since the fold induction of AGS-AC1+dox following 
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hypoxia seems not be simply the sum of AGS-AC1+dox in normoxic 
conditions and AGS-AC1–dox following hypoxia, we hypothesized that the 
presence of the protein was an important element to have further induction of 
expression not only by HIF-1α activation but also by TFF1 itself. 
 
 
 
Figure 5.10: A, RT-PCR for TFF1 mRNA expression in AGS-AC1 cells after 24-48-
72h of hypoxia, measured on mRNA levels of HPRT in the same experimental 
models. * p<0.05, **p<0.01 and *** p<0.001 vs AGS-AC1cells in normoxia, $ p<0.05 
and $$ p<0.01 vs AGS-AC1 induced cells in normoxia. B, Western blot using 
antibody against TFF1 protein extracts from AGS-AC1 cells exposed to hypoxia for 
24-48-72h. Protein normalization was performed on GAPDH levels.  
 
 
To investigate the TFF1 autoinduction mechanism we performed a 
Luciferase reporter assay on AGS-AC1. Therefore, the cells were co-
transfected with a pGL3 commercial plasmid (Promega) containing TFF1 
promoter wild type fragments of different lengths upstream of a Luciferase 
reporter gene and with a plasmid containing the β-galactosidase gene, whose 
expression was used as a normalization parameter of transfection efficiency. 
The pGL3 constructs were obtained as described in Materials and Methods 
section and they contained respectively fragments corresponding to -1036 bp, 
-830 bp, -586 bp and -212 bp of the TFF1 promoter (fig. 5.11). 
The luciferase activity of AGS-AC1 cells induced or not with 
doxycycline and transfected with the various constructs is reported in figure 
5.11. Data are expressed as fold increment of pGL3(-212)Luc, considered as 
a basal level and set to 1.  
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Figure 5.11: A, Schematic representation of luciferase reporter constructs containing 
fragments of varying lengths from −1036 to −212 of the TFF1 promoter upstream of a 
Luciferase reporter gene; B. Luciferase reporter assays in AGS-AC1 cells. TFF1 
induction of cells was performed with doxycycline (1 μg/mL).  
All data are representative of experiments carried out in quadruplicate and are 
depicted as mean ± SD. * p < 0.05, ** p < 0.01 compared with non induced cells 
expressing pGL3(−212)Luc.  
 
 
We observed that luciferase activities of AGS-AC1 induced cells were 
higher than that of the non induced ones. From data in fig. 5.11 we can 
conclude that an element responsive to TFF1 protein is present between -583 
and -212 bp. Moreover we can also hypothesize that an element able to 
suppress this activity is located between -830 and -583 bp. 
This region of about 0.6 kb contains, as described in the literature, two 
HIF-1α binding sites [199], so this sequence is also responsible of hypoxia 
up-regulation of TFF1 (fig. 5.12). 
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Figure 5.12: Representation of -583 to -17 bp region of the promoter of TFF1;  
the transcriptional start site and the main regulatory factors are indicated. 
 
 
To verify that this region was responsible for the induction of TFF1 not 
only by HIF1-α, but also by TFF1 itself in hypoxic environment and that this 
two mechanisms contribute to TFF1 regulation, we performed a Luciferase 
reporter assay on AGS-AC1 with pGL3(−583)Luc construct in hypoxic 
condition. 
For experimental reasons, we mimicked the hypoxic condition by using 
the chemical hypoxia-inducer cobalt chloride (CoCl2) and verified that it gave 
the same TFF1 induction of the hypoxic-chamber. 48 hours after transfection, 
cells were incubated in the presence or absence of CoCl2 (200 μM), and the 
assays were carried out after 8, 16, 24 hours from the treatment.  
In figure 5.13 data relative to luciferase activity of the transfected cells 
are reported.  
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Figure 5.13: A, Western blot using antibody against TFF1 on protein extracts from 
AGS-AC1 cells  +/- doxyxycline 1 μg/mL after 72h of treatment with 200 μM CoCl2. 
Protein normalization was performed on GAPDH levels. B, Schematic representation 
of luciferase reporter construct of pGL3(-583)Luc, containing wild type promoter 
sequences from − 583 to − 17 of the TFF1 promoter upstream of a Luciferase 
reporter gene; C. Luciferase reporter assays with pGL3(-583)Luc and CoCl2 (200 μM) 
exposure for 8, 16, 24 hours in AGS-AC1 cells. TFF1 induction of cells was 
performed with doxycycline (1 μg/mL). All data are representative of experiments 
carried out in quadruplicate and are reported as mean ± SD. *p ≤ 0.05, **p ≤ 0.01 vs 
non induced cells, $$$ p ≤ 0.001 vs induced cells. 
 
 
In AGS-AC1 TFF1 overexpressing cells we had, as expected, a 
significant increase in luciferase activity respect to non-induced cells. The 
CoCl2 treatment induced luciferase activity in non induced AGS-AC1 cells, but 
at higher levels in the induced ones (fig. 5.13).  
These results suggest, the involvement of this region of TFF1 
promoter in a self-induction mechanism that works also during hypoxia and 
synergistically with HIF1-α induction. 
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In order to definitively assess the effect of TFF1 on its own promoter, 
we added different concentrations of TFF1 recombinant dimeric protein to 
AGS cells transiently transfected with TFF1 promoter-luciferase reporter 
construct. We observed a significantly higher luciferase activity of cells treated 
with hrTFF1 than that of the untreated ones and this effect was dose-
dependent (fig. 5.14).  
 
 
Figure 5.14: Luciferase reporter assay with pGL3(583)Luc in AGS cells. At 48h post-
transfection, cells were stimulated with different concentrations of hrTFF1 (0-4 μg/mL) 
for 24h.  All data are representative of experiments carried out in quadruplicate and 
are depicted as mean ± SD. *p<0.05, **p<0.01 vs control cells (0 μg/mL). 
 
 
5.10 TFF1 regulates the methylation status of its DNA 
 
Epigenetic factors such as DNA methylation play an important role in 
regulating gene expression. Aberrant DNA methylation is a feature of a 
number of important human diseases, including cancer.  
Several works show the dependence of TFF1 expression from the 
methylation status of its promoter. Bisulfite sequencing was performed to 
explore DNA methylation of TFF1 in AGS-AC1 clone to investigate its 
changes after induction of TFF1 expression and in hypoxic condition. The 
bisulfite converts the unmethylated cytosines into uracil, leaving unmodified 
the methylated cytosines, so the unmethylated DNA will have a lower melting 
temperature compared to methylated one, since the A-T base pairing requires 
less energy to be denatured compared to the C-G base pairing. An HRM 
analysis, based on these differences, was performed on TFF1 promoter in 
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AGS-AC1 after 72h from induction with doxycyline and/or treatment with 
CoCl2. 
 The difference plots in figure 5.15 showed the different curves of DNA 
methylation. Following TFF1 induction, AGS-AC1 cells showed a reduction of 
the percentage of methylation compared to the uninduced clone. Also the 
treatment with the hypoxia-inducer CoCl2 was able to reduce the methylation 
status of both the control and the induced cells but in the induced ones the 
reduction of methylation was greater. Therefore the trefoil peptide can 
autoactivate, at least partly, its own expression regulating the density of 
methylated CpGs. Hypoxia, through HIF1-α activation, creates a loop with 
more TFF1 induction and conseguent lesser DNA methylation. 
 
 
 
 
Figure 5.15: Difference plots of DNA methylation pattern of TFF1 in AGS-AC1 cells 
after 72h of induction with doxycycline (1 μg/mL) and/or with CoCl2 200 μM. 
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Upper, difference plot of standard DNA samples. Lower, difference plot of HRM on 
AGS-AC1 cells.  
 
 
5.11 TFF receptor: a possible role for FPR? 
 
Currently direct receptors of TFFs are not yet identified. Trefoil factors 
are expressed at high levels on the apical surface of the gastrointestinal tract, 
suggesting that their association with high-affinity receptors could be critical. 
Dubeykovskaya and coworkers [200] have identified for the first time CXCR4 
as a possible TFF2 receptor in epithelial tumor cells and lymphocytes.  
We decided to investigate a possible role for N-formyl peptide 
receptors (FPR1, FPR2 and FPR3). The Formyl Peptide Receptors (FPR) is a 
class of trans-membrane seven domains receptors, coupled to G protein 
(GPCR), involved in the innate immunity, inflammation and cancer. Several 
studies suggest a role of FPR in the progression of various cancers, including 
gastric cancer, for which has been described a positive correlation with a 
specific polymorphism of FPR1 [201]. It was also demonstrated that FPR are 
expressed in gastric epithelium and are necessary for the repair and 
restitution of the barrier integrity [202]. Hence, the idea of investigating a 
possible relationship between FPR and TFF1. 
We first evaluated the basal expression of FPR in the AGS-AC1 clone 
by Real Time PCR (RT-PCR) (fig. 5.16). Following TFF1 induction we had not 
found any change of the expression levels of FPR1 and 3, but a significant, 
although slight, increase in the expression of FPR2.  
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Figure 5.16: RT-PCR for TFF1 and FPR mRNA expression in AGS-AC1cells, 
induced or not with doxycycline (1 μg/mL) for 48 hours. Bars represent the mean ± 
SD of mRNA relative to HPRT mRNA levels. *p<0.05 and ***p <0.001 vs AGS-AC1 
non induced cells. 
 
 
To evaluate whether they could play a role in cell invasion processes 
and be the likely receptors through which TFF1 exerts its action, we 
performed the invasion assays using FPR pharmacological antagonist Boc-2 
(Boc-FLFLF, 50 μM) (fig. 5.17). Following treatment with the antagonist we 
didn‘t find any change in the rate of invasion in the control cells, while, in 
induced cells, the antagonist reverts the increase caused by TFF1 hyper-
expression (fig. 5.17). 
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Figure 5.17: Invasion of AGS-AC1 gastric cancer cell lines through Matrigel. 
Induction with doxycycline (1 μg/mL), treatment with 50 μM Boc-2. 
Upper panel, bottom surface of filters stained with crystal violet. Lower panel, 
quantification of invasive cells. *** p<0.001 vs untreated control and $ p<0.001 vs 
AGS-AC1 induced cells.  
 
 
This suggests that the FPR receptors could have a role in the pro-
invasive activity of TFF1.  
In addition, by RT-PCR, we observed an up-regulation of all FPRs in 
AGS when treated with the recombinant protein TFF1 for 72h (fig. 5.18). 
 
 
CHAPTER 5                                                                                                      Results 
  
- 53 - 
 
 
 
Figure 5.18: RT-PCR for FPR1, 2, 3 mRNA expression in AGS cells, after treatment 
with hrTFF1 (4 μg/mL) for 72 hours. Bars represent the mean ± SD of mRNA relative 
to HPRT mRNA levels. *p< 0.05 and **p<0.01 vs untreated control. 
 
 
These findings are in agreement with a possible linking between TFF1 
and FPR, but further studies are necessary to demonstrate a direct interaction 
between these two proteins.  
 
 
5.12 TFF1 induces EMT process in prostate cancer cell model 
 
As previously described, TFF1 is reported to have a role in the 
development of a variety of solid tumors, including prostate cancer. To 
investigale the role of the peptide in the tumor development outside the 
gastric context, we used a particular model of human prostate cancer, ARCaP 
E cell line. This cell line is a subline of ARCaP cells, an androgen-repressed 
human prostate cancer cell line derived from ascites fluid of a pazient with 
metastatic disease, and represents an advanced and highly metastatic form 
of prostate cancer [203]; ARCaP E cells express a host of human prostate 
cancer biomarkers  and undergo EMT on exposure to soluble factors or host 
bone microenvironment. Thus, it is an ideal model for studying abnormal EMT 
or EMT-like changes during prostate progression and metastasis. 
We treated ARCaP E with TFF1 recombinant protein for 72 hours and 
then evaluated the expression of the main EMT marker. By western blotting, 
we confirmed that TFF1 was able to induce EMT also in this cellular model. In 
fact, we observed a phenotypic change of the cells following TFF1 
administration (fig 5.19, upper panel), corroborated by E-cadherin down-
regulation, vimentin up-regulation and a significant reduction of the two 
epithelial cytokeratins CK8 and CK18 (fig 5.19, lower panel). 
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Figure 5.19: Upper panel, images in clear field at microscope of ARCaP E at 72h of 
treatment with hrTFF1 (4-8  μg/mL). Lower panel, Western blot using antibody against 
E-cadherin, vimentin, CK-8, CK-18 on protein extracts from ARCaP E at 72h of 
treatment with hrTFF1. Protein normalization was performed on GAPDH levels. 
 Densitometric analysis was performed with ImageJ software and relative E-cadherin, 
vimentin, CK-8, CK-18 band intensity normalized to GAPDH and quantified with 
respect to controls (untreated) set to 1.0. Bars represent the mean ± SD. Statistically 
significant differences at p<0.05 from the untreated cells are indicated (*). 
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CHAPTER 6 
 
DISCUSSION  
 
The human trefoil peptide, TFF1, is normally highly expressed in the 
gastrointestinal tract to ensure mucosal defence and epithelial integrity. 
However, it has been reported its aberrant expression in several epithelial 
neoplasias. In this context, TFF1 performs multiple functions in tumor 
development and/or progression and it appears to behave either as a tumour 
suppressor or an oncogenic gene. However, more studies are required to 
investigate the role of TFF1 in cancer progression since its mechanism of 
action has not yet been completely clarified. 
This study was undertaken to bring additional insights in TFF1 role in 
gastric cancer. Gastric cancer is one of the most common malignancies in the 
world and has a high rate of metastasis. Gastric cancer cells can metastasize 
to nearby organs such as pancreas, liver and transverse colon as well as to 
distant lymph nodes and bone tissue.  
In gastric cancer, TFF1 is largely considered a tumor suppressor, 
whose expression is remarkably down-regulated due to loss of heterozygosity 
and promoter methylation. Conversely, the peptide is reported to be 
expressed in 50% of gastric cancer, up-regulated in metastatic gastric cancer 
compared with the primary cancer and in gastric cancer associated with 
lymph node metastasis. Im and coworkers reported a much higher frequency 
of TFF1 expression in undifferentiated and diffuse types of gastric cancer 
compared with differentiated and intestinal types of gastric cancer [204]. In 
addition, Suarez and coworkers reported that high intratumoral TFF1 levels 
were significantly associated with unfavourable outcome in patients with 
primary gastric adenocarcinomas [117]. Outside the gastrointestinal tract, 
TFF1 is associated with a more invasive, metastatic and aggressive 
phenotype in colon, prostate and pancreatic cancer.  
 We started from the hypothesis that gastric tumors where TFF1 is not 
down-regulated may be able to benefit from the presence of the trefoil protein 
taking advantage of its migratory, invasive and antiapoptotic functions.  
In this work we demonstrated that TFF1 stimulates invasiveness and 
metastatic behaviour of gastric cancer cells. In particular, TFF1 promotes 
invasion of AGS cells and of an inducible TFF1-hyperexpressing cell clone, 
AGS-AC1, both in autocrine and paracrine manner. Moreover, the pro-
invasive activity of TFF1 is associated with a greater MMP-2 activity. 
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Overexpression of MMP-2 and -9 as well as activation of proMMP-2 to 
active MMP-2 is one of the major features of the malignant phenotype in both 
colorectal and gastric cancer. Different studies showed that TFF3 increases 
the expression of MMPs to promote cell migration [205, 206]. Here, we 
observed that TFF1 may work in a similar manner, regulating activation of 
MMP-2 for invasion and subsequently for metastasis. At the base of the cell 
invasion process there is the loss of cell-cell adhesion capacity. Tumor 
invasion and metastasis frequently coincide with the loss of E-cadherin-
mediated cell-cell adhesion. E-cadherin is the main adhesion molecule in 
adherens junctions of epithelia and is often down-regulated in cancers. This 
event, along with other cytoskeletal modifications, drives to the EMT process, 
with the loss of epithelial characteristics and gain of a migratory and invasive 
mesenchymal phenotype.  
We demonstrated that TFF1 is implicated in the occurrence of EMT in 
our cell model, with loss of epithelial characteristics and gain of a 
mesenchymal morphological phenotype. After treatment of AGS cells with 
TFF1, we observed the reduction of E-cadherin and of other epithelial 
markers such as cytokeratins 8 and 18, proteins of intermediate filaments 
forming the skeleton of epithelial cells, providing support to maintain cell 
integrity and the structure of epithelial tissues. In parallel, we found an 
increase of the mesenchymal markers such as vimentin and an upregulation 
of significant transcription factors of EMT, as Snail, ZEB1, and Nanog. These 
factors act as molecular switches, respond to the known signaling pathways 
and regulate the EMT program. All these molecular and structural changes 
correlate with tumour progression and poor outcome. In high-risk GC patients, 
loss of E-cadherin expression and aberrant expression of Snail and vimentin 
are significantly associated with aggressive clinicopathologic features, 
vascular invasion and lymph node metastasis. 
 TFF1 is able to induce EMT not only in the GC models but also in a 
prostate cancer cell line, suggesting that its presence, both in the 
gastrointestinal tract and in other organs, may be associated with a more 
aggressive tumoral phenotype.  
TFF1 is able to form homodimers, which are biologically more active 
than monomers, moreover it binds copper ions through its C-terminal tail and 
this interaction influences homodimer formation and its motogenic activity. 
Here, we demonstrated that copper is also essential for the invasive activity of 
TFF1. Interestingly, the chelation of copper is able to inhibit its invasive 
activity preventing the formation of the TFF1-copper complex, even in the 
presence of homodimers. This is a new step in the comprehension of TFF1 
mechanisms of action. Copper is a key component of many essential proteins 
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and there is growing evidence that Cu directly influences the ability of 
cancerous cells to invade and metastasize. In particular, it was reported the 
implication of the Cu-dependent proteins LOX (Lysyl oxidase), SPARC 
(secreted protein acidic and rich in cysteine), and MEMO (mediator of ErbB2-
driven cell motility) in cancer metastasis [174, 207, 208]. Blockhuys and 
coworkers demonstrated that also the Cu chaperone Atox1 plays an essential 
role in breast cancer cell migration [177]. Furthermore, serum and tumor 
copper levels are significantly elevated in a variety of cancers, including 
gastric cancer and copper depletion is a validated and useful strategy to 
target cancer. Understanding the importance and the biological relevance of 
TFF1-copper interaction in tumor development and progression may be of 
great utility for anti-tumor therapeutic approaches. 
Hypoxia is a characteristic feature of locally advanced solid tumors 
and, through activation of hypoxia-related pathways, cancer cells adapt to 
these condition acquiring a more aggressive tumor phenotype, resistance to 
chemotherapy, and poor clinical outcomes. Moreover, TFF1, TFF2 and TFF3 
gene expression has been demonstrated to be up-regulated in a HIF-1α-
dependent manner during hypoxia [199]. 
Here we reported that, in hypoxic condition, a significant increase of 
TFF1 expression is associated with hypoxia-related mesenchymal-metastatic 
process. TFF1 may act as a key signalling factor in modulating cell 
characteristics and behaviour in response to hypoxia. 
Furthermore, TFF1 is able to regulate its own expression, in normoxic 
as hypoxic condition, with an auto-induction mechanism also promoting a 
reduction of its promoter methylation. In gastric cell lines, the trefoil factors 
respond to auto- and cross-induction through cis-acting regulatory regions. It 
has been identified a TFF2/SP response element within the 823 bp upstream 
of TFF2 transcriptional start site [209]. Moreover, recently Sun and coworkers 
have identified the −1450 bp to −1400 bp fragment of the TFF3 promoter as 
functional region for its self-induction [210]. In a similar manner, we 
demonstrated that also TFF1 exhibits an auto-induction mechanism and we 
identified the element responsive to the auto-stimulation.  It is located within 
the 0.6kb (-583bp to -17bp) 5‘-flanking region of its promoter and is 
responsive to the presence of the protein and able to positively regulate the 
expression of TFF1 also during hypoxia and synergistically with HIF1-α 
induction. Additionally, we observed that TFF1 can regulate the methylation 
status of its promoter. We hypothesized that it can auto-activate its own 
expression regulating the density of methylated CpGs.  
The auto-induction mechanism can be a critical component for tumor 
progression, since it may result in elevated levels of TFF1 in the tumor 
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microenvironment through a positive feedback loop. In this way, it creates a 
―vicious cycle‖ in which the presence of TFF1 in the tumor will lead to an 
accumulation of protein making the tumor more aggressive. 
Finally, we investigated the relationship between TFF1 and the N-
formyl peptide receptors (FPR), in an attempt to identify the potential 
receptors of TFF1. FPRs are G-protein-coupled receptors that have a role in 
innate immunity and inflammation. Besides their involvement in inflammatory 
disorders, FPRs have been implicated in the regulation of tissue repair and 
angiogenesis. Recently it has been reported the involvement of FPRs in 
cancer. In particular, a positive association between a specific FPR1 
polymorphism and gastric cancer has recently been described [201]. 
Furthermore, Prevete N. and coworkers demonstrated that FPRs activation 
induces EMT, cell proliferation, survival and invasiveness of gastric cancer 
cells [202]. 
For the first time we reported a functional relationship between TFF1 
and FPRs. We found that exogenous TFF1 in AGS cells induces FPR 
expression and FPRs influence the pro-invasive activity of TFF1. This 
evidence supports our hypothesis of a ligand-receptor interaction between 
TFF1 and FPRs but further studies are needed to demonstrate the direct 
binding of these two proteins and the downstream molecular mechanisms. 
In conclusion, we have shown that TFF1 may be involved in the tumor 
progression of gastric cancer cells, stimulating invasion and EMT and 
modulating cell characteristics and behaviour in response to hypoxia. Our 
observations add a significant new understanding to the multifaceted role of 
TFF1 in gastric cancer, suggesting a possible oncogenic function of the 
peptide. Our data are in line with the clinical evidence of the association of 
TFF1 with advanced and metastatic GC, noting that the presence of the trefoil 
peptide promotes the invasion and EMT processes. Thus, gastric cancers in 
which TFF1 is not down-regulated can exploit the migratory and invasive 
functions of TFF1 for their progression. 
Moreover, copper influence on TFF1 action is a new finding in the 
intricate comprehension of functions attributed to this family of peptides. 
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